share_log

Benzinga's Top Upgrades, Downgrades For August 20, 2020

Benzinga's Top Upgrades, Downgrades For August 20, 2020

賓辛加的頂級升級，2020 年 8 月 20 日降級
Benzinga Real-time News ·  2020/08/20 21:51

Upgrades

升級

  • For Cinemark Holdings Inc (NYSE:CNK), Benchmark upgraded the previous rating of Hold to the current rating Buy. For the second quarter, Cinemark Hldgs had an EPS of $1.27, compared to year-ago quarter EPS of $0.86. The stock has a 52-week-high of $39.81 and a 52-week-low of $5.71. At the end of the last trading period, Cinemark Hldgs closed at $11.14.
  • For OGE Energy Corp (NYSE:OGE), Guggenheim upgraded the previous rating of Neutral to the current rating Buy. OGE Energy earned $0.51 in the second quarter, compared to $0.50 in the year-ago quarter. The stock has a 52-week-high of $46.43 and a 52-week-low of $23.00. At the end of the last trading period, OGE Energy closed at $32.08.
  • According to Northland Capital Markets, the prior rating for Power Integrations Inc (NASDAQ:POWI) was changed from Underperform to Market Perform. For the second quarter, Power Integrations had an EPS of $0.66, compared to year-ago quarter EPS of $0.56. At the moment, the stock has a 52-week-high of $127.39 and a 52-week-low of $56.88. Power Integrations closed at $57.30 at the end of the last trading period.
  • According to DBS Bank, the prior rating for Sea Ltd (NYSE:SE) was changed from Sell to Buy. For the second quarter, Sea had an EPS of $0.68, compared to year-ago quarter EPS of $0.68. At the moment, the stock has a 52-week-high of $154.25 and a 52-week-low of $26.41. Sea closed at $150.58 at the end of the last trading period.
  • For Shake Shack Inc (NYSE:SHAK), Wedbush upgraded the previous rating of Neutral to the current rating Outperform. For the second quarter, Shake Shack had an EPS of $0.45, compared to year-ago quarter EPS of $0.27. The current stock performance of Shake Shack shows a 52-week-high of $105.84 and a 52-week-low of $30.01. Moreover, at the end of the last trading period, the closing price was at $53.87.
  • According to Barclays, the prior rating for Dana Inc (NYSE:DAN) was changed from Equal-Weight to Overweight. In the second quarter, Dana showed an EPS of $0.69, compared to $0.87 from the year-ago quarter. The stock has a 52-week-high of $19.21 and a 52-week-low of $4.22. At the end of the last trading period, Dana closed at $13.17.
  • For Elanco Animal Health Inc (NYSE:ELAN), Morgan Stanley upgraded the previous rating of Equal-Weight to the current rating Overweight. For the second quarter, Elanco Animal Health had an EPS of $0.09, compared to year-ago quarter EPS of $0.28. At the moment, the stock has a 52-week-high of $32.66 and a 52-week-low of $15.17. Elanco Animal Health closed at $25.80 at the end of the last trading period.
  • 為Cinemark控股公司(紐約證券交易所：CNK)，Benchmark將之前的持有評級上調至當前評級買入。第二季度，Cinemark Hldgs的每股收益為1.27美元，而去年同期為0.86美元。該股52周高點為39.81美元，52周低點為5.71美元。在最後一個交易期結束時，Cinemark Hldgs收於11.14美元。
  • 為OGE能源公司(紐約證券交易所：OGE)，Guggenheim將之前的中性評級上調至當前評級買入。OGE Energy第二季度盈利0.51美元，而去年同期為0.50美元。該股目前的52周高點為46.43美元，52周低點為23.00美元。上一交易期尾盤，OGE Energy收報32.08美元。
  • 根據Northland Capital Markets的數據，之前的評級為Power Integrations Inc.(納斯達克：戰俘)從表現不佳改為市場表現。第二季度，Power Integrations的每股收益為0.66美元，而去年同期為0.56美元。目前，該股的52周高點為127.39美元，52周低點為56.88美元。Power Integrations上一交易日尾盤報57.30美元。
  • 根據星展銀行的先前評級，SEA有限公司(紐約證券交易所：硒)從賣出改為買入。第二季度，Sea的每股收益為0.68美元，而去年同期為0.68美元。目前，該股的52周高點為154.25美元，52周低點為26.41美元。SEA上一交易期尾盤報150.58美元。
  • 為Shake Shack Inc.(紐約證券交易所：搖動)，韋德布什將之前的評級上調為中性，至當前評級強於大盤。第二季度，Shake Shack的每股收益為0.45美元，而去年同期為0.27美元。目前Shake Shack的股票表現顯示，52周高點為105.84美元，52周低點為30.01美元。此外，在上一交易期結束時，收盤價為53.87美元。
  • 根據巴克萊的説法，之前的評級為Dana Inc.(紐約證券交易所：丹)從等重改為超重。第二季度，戴納公司的每股收益為0.69美元，而去年同期為0.87美元。該股52周高點為19.21美元，52周低點為4.22美元。上一交易期結束時，達納收盤報13.17美元。
  • 為Elanco動物健康公司(紐約證券交易所：伊蘭)，摩根士丹利將此前評級為持平上調至當前評級增持。第二季度，Elanco Animal Health的每股收益為0.09美元，而去年同期為0.28美元。目前，該股的股價為32.66美元的52周高點和15.17美元的52周低點。Elanco Animal Health上一交易期尾盤報25.80美元。

 

Downgrades

評級下調

  • For Vipshop Holdings Ltd (NYSE:VIPS), JP Morgan downgraded the previous rating of Overweight to the current rating Neutral. For the second quarter, Vipshop Holdings had an EPS of $0.27, compared to year-ago quarter EPS of $0.23. The stock has a 52-week-high of $24.46 and a 52-week-low of $7.69. At the end of the last trading period, Vipshop Holdings closed at $19.26.
  • According to Raymond James, the prior rating for Ventas Inc (NYSE:VTR) was changed from Strong Buy to Outperform. Ventas earned $0.77 in the second quarter, compared to $0.97 in the year-ago quarter. At the moment, the stock has a 52-week-high of $75.40 and a 52-week-low of $13.35. Ventas closed at $40.38 at the end of the last trading period.
  • According to Benchmark, the prior rating for Regeneron Pharmaceuticals Inc (NASDAQ:REGN) was changed from Buy to Hold. For the second quarter, Regeneron Pharmaceuticals had an EPS of $7.16, compared to year-ago quarter EPS of $6.04. The current stock performance of Regeneron Pharmaceuticals shows a 52-week-high of $664.64 and a 52-week-low of $271.37. Moreover, at the end of the last trading period, the closing price was at $629.63.
  • For Biomarin Pharmaceutical Inc (NASDAQ:BMRN), RBC Capital downgraded the previous rating of Outperform to the current rating Sector Perform. Biomarin Pharmaceutical earned $0.16 in the second quarter, compared to $0.29 in the year-ago quarter. The current stock performance of Biomarin Pharmaceutical shows a 52-week-high of $131.94 and a 52-week-low of $62.88. Moreover, at the end of the last trading period, the closing price was at $76.72.
  • Wells Fargo downgraded the previous rating for Crown Castle International Corp (NYSE:CCI) from Overweight to Equal-Weight. In the second quarter, Crown Castle Intl showed an EPS of $1.45, compared to $1.41 from the year-ago quarter. The stock has a 52-week-high of $180.00 and a 52-week-low of $114.18. At the end of the last trading period, Crown Castle Intl closed at $162.69.
  • For Momenta Pharmaceuticals Inc (NASDAQ:MNTA), Stifel downgraded the previous rating of Buy to the current rating Hold. Momenta Pharmaceuticals earned $0.48 in the second quarter, compared to $1.16 in the year-ago quarter. The current stock performance of Momenta Pharmaceuticals shows a 52-week-high of $52.21 and a 52-week-low of $11.91. Moreover, at the end of the last trading period, the closing price was at $52.12.
  • For Principia Biopharma Inc (NASDAQ:PRNB), Stifel downgraded the previous rating of Buy to the current rating Hold. Principia Biopharma earned $0.31 in the second quarter, compared to $0.28 in the year-ago quarter. The stock has a 52-week-high of $100.04 and a 52-week-low of $25.35. At the end of the last trading period, Principia Biopharma closed at $99.70.
  • For Teligent Inc (NASDAQ:TLGT), Craig-Hallum downgraded the previous rating of Buy to the current rating Hold. Teligent earned $1.54 in the second quarter, compared to $0.04 in the year-ago quarter. At the moment, the stock has a 52-week-high of $5.94 and a 52-week-low of $0.19. Teligent closed at $2.01 at the end of the last trading period.
  • Credit Suisse downgraded the previous rating for Sarepta Therapeutics Inc (NASDAQ:SRPT) from Outperform to Neutral. In the second quarter, Sarepta Therapeutics showed an EPS of $1.51, compared to $0.83 from the year-ago quarter. The stock has a 52-week-high of $175.00 and a 52-week-low of $72.05. At the end of the last trading period, Sarepta Therapeutics closed at $148.66.
  • 為唯品會控股有限公司(紐約證券交易所：貴賓)，摩根大通將之前的評級下調至增持至當前評級中性。第二季度，唯品會控股的每股收益為0.27美元，而去年同期為0.23美元。該股目前的52周高點為24.46美元，52周低點為7.69美元。上一交易日尾盤，唯品會控股收報19.26美元。
  • 根據Raymond James的説法，之前的評級為Ventas Inc.(紐約證券交易所：錄像機)從強勢買入變為強於大盤。Ventas第二季度的利潤為0.77美元，而去年同期為0.97美元。目前，該股的股價為75.40美元的52周高點和13.35美元的52周低點。Ventas上一交易期尾盤報40.38美元。
  • 根據基準，之前的評級為Regeneron製藥公司(納斯達克：註冊)已從買入更改為持有。第二季度，Regeneron製藥公司的每股收益為7.16美元，而去年同期為6.04美元。Regeneron PharmPharmticals目前的股票表現顯示，52周高點為664.64美元，52周低點為271.37美元。此外，在上一交易期結束時，收盤價為629.63美元。
  • 為BioMarin製藥公司(納斯達克：BMRN)，RBC Capital將之前的評級下調為表現優於大盤，至當前評級板塊表現。BioMarin製藥公司第二季度的利潤為0.16美元，而去年同期為0.29美元。BioMarin Pharmtics目前的股票表現顯示，52周高點為131.94美元，52周低點為62.88美元。此外，在上一交易期結束時，收盤價為76.72美元。
  • 富國銀行下調了之前的評級為冠城(紐約證券交易所：CCI從超重到等重。第二季度，Crown Castle Intl的每股收益為1.45美元，而去年同期為1.41美元。該股目前的52周高點為180.00美元，52周低點為114.18美元。上一交易期結束時，皇冠城堡國際收盤報162.69美元。
  • 為Momenta製藥公司(納斯達克：MNTA)，Stifel將之前對Buy的評級下調至目前的評級持有。Momenta製藥公司第二季度的利潤為0.48美元，而去年同期為1.16美元。Momenta PharmPharmticals目前的股票表現顯示，52周高點為52.21美元，52周低點為11.91美元。此外，在上一交易期結束時，收盤價為52.12美元。
  • 為Printia Biophma公司(納斯達克：PRNB)，Stifel將之前對Buy的評級下調至目前的評級持有。Printia Biophma第二季度的利潤為0.31美元，而去年同期為0.28美元。該股目前的52周高點為100.04美元，52周低點為25.35美元。在上個交易期結束時，普林西婭Biophma收於99.70美元。
  • 為泰利格特公司(納斯達克：TLGT)，Craig-Hallum將之前對Buy的評級下調至目前的評級持有。泰利金特第二季度的利潤為1.54美元，而去年同期為0.04美元。目前，該股的52周高點為5.94美元，52周低點為0.19美元。泰利根上交易日尾盤報2.01美元。
  • 瑞士信貸下調了之前的評級為Sarepta治療公司(納斯達克：SRPT)從跑贏大盤到中性。第二季度，Sarepta治療公司的每股收益為1.51美元，而去年同期為0.83美元。該股52周高點為175.00美元，52周低點為72.05美元。在上一交易期結束時，賽瑞普塔治療公司收於148.66美元。

 

Initiations

啟蒙行動

  • Deutsche Bank initiated coverage on Check Point Software Technologies Ltd (NASDAQ:CHKP) with a Hold rating. The price target for Check Point Software is set to $128.00. Check Point Software earned $1.58 in the second quarter, compared to $1.38 in the year-ago quarter. The current stock performance of Check Point Software shows a 52-week-high of $130.65 and a 52-week-low of $80.06. Moreover, at the end of the last trading period, the closing price was at $128.08.
  • With a current rating of Outperform, Evercore ISI Group initiated coverage on 8x8 Inc (NYSE:EGHT). The price target seems to have been set at $23.00 for 8x8. 8x8 earned $0.07 in the first quarter, compared to $0.14 in the year-ago quarter. The stock has a 52-week-high of $25.25 and a 52-week-low of $10.70. At the end of the last trading period, 8x8 closed at $16.28.
  • Morgan Stanley initiated coverage on ACADIA Pharmaceuticals Inc (NASDAQ:ACAD) with an Overweight rating. The price target for ACADIA Pharmaceuticals is set to $55.00. In the second quarter, ACADIA Pharmaceuticals showed an EPS of $0.27, compared to $0.38 from the year-ago quarter. The current stock performance of ACADIA Pharmaceuticals shows a 52-week-high of $58.72 and a 52-week-low of $23.77. Moreover, at the end of the last trading period, the closing price was at $38.91.
  • Deutsche Bank initiated coverage on Fortinet Inc (NASDAQ:FTNT) with a Hold rating. The price target for Fortinet is set to $131.00. Fortinet earned $0.82 in the second quarter, compared to $0.58 in the year-ago quarter. The current stock performance of Fortinet shows a 52-week-high of $151.95 and a 52-week-low of $70.20. Moreover, at the end of the last trading period, the closing price was at $129.51.
  • Needham initiated coverage on Vir Biotechnology Inc (NASDAQ:VIR) with a Buy rating. The price target for Vir Biotechnology is set to $62.00. Vir Biotechnology earned $0.27 in the second quarter. At the moment, the stock has a 52-week-high of $75.00 and a 52-week-low of $11.65. Vir Biotechnology closed at $50.43 at the end of the last trading period.
  • Morgan Stanley initiated coverage on Evofem Biosciences Inc (NASDAQ:EVFM) with a Equal-Weight rating. In the second quarter, Evofem Biosciences showed an EPS of $0.39, compared to $0.95 from the year-ago quarter. The stock has a 52-week-high of $7.50 and a 52-week-low of $2.73. At the end of the last trading period, Evofem Biosciences closed at $3.36.
  • With a current rating of In-Line, Evercore ISI Group initiated coverage on Five9 Inc (NASDAQ:FIVN). The price target seems to have been set at $122.00 for Five9. For the second quarter, Five9 had an EPS of $0.21, compared to year-ago quarter EPS of $0.20. The stock has a 52-week-high of $131.98 and a 52-week-low of $50.73. At the end of the last trading period, Five9 closed at $124.59.
  • Oppenheimer initiated coverage on Fulgent Genetics Inc (NASDAQ:FLGT) with an Outperform rating. The price target for Fulgent Genetics is set to $75.00. Fulgent Genetics earned $0.17 in the second quarter, compared to $0.06 in the year-ago quarter. At the moment, the stock has a 52-week-high of $47.85 and a 52-week-low of $6.70. Fulgent Genetics closed at $44.01 at the end of the last trading period.
  • Goldman Sachs initiated coverage on Flexion Therapeutics Inc (NASDAQ:FLXN) with a Neutral rating. The price target for Flexion Therapeutics is set to $15.00. Flexion Therapeutics earned $0.76 in the second quarter, compared to $0.96 in the year-ago quarter. The current stock performance of Flexion Therapeutics shows a 52-week-high of $22.98 and a 52-week-low of $5.01. Moreover, at the end of the last trading period, the closing price was at $12.65.
  • With a current rating of Overweight, Wells Fargo initiated coverage on Tandem Diabetes Care Inc (NASDAQ:TNDM). The price target seems to have been set at $120.00 for Tandem Diabetes Care. For the second quarter, Tandem Diabetes Care had an EPS of $0.45, compared to year-ago quarter EPS of $0.03. The stock has a 52-week-high of $110.80 and a 52-week-low of $43.69. At the end of the last trading period, Tandem Diabetes Care closed at $107.33.
  • Berenberg initiated coverage on Eaton Corp PLC (NYSE:ETN) with a Hold rating. The price target for Eaton Corp is set to $110.00. Eaton Corp earned $0.70 in the second quarter, compared to $1.53 in the year-ago quarter. At the moment, the stock has a 52-week-high of $105.78 and a 52-week-low of $56.41. Eaton Corp closed at $100.48 at the end of the last trading period.
  • With a current rating of Buy, Berenberg initiated coverage on Emerson Electric Co (NYSE:EMR). The price target seems to have been set at $83.00 for Emerson Electric. For the third quarter, Emerson Electric had an EPS of $0.80, compared to year-ago quarter EPS of $0.94. The current stock performance of Emerson Electric shows a 52-week-high of $78.38 and a 52-week-low of $37.75. Moreover, at the end of the last trading period, the closing price was at $68.32.
  • With a current rating of Buy, Berenberg initiated coverage on Rockwell Automation Inc (NYSE:ROK). The price target seems to have been set at $270.00 for Rockwell Automation. In the third quarter, Rockwell Automation showed an EPS of $1.27, compared to $2.40 from the year-ago quarter. At the moment, the stock has a 52-week-high of $238.49 and a 52-week-low of $115.38. Rockwell Automation closed at $228.68 at the end of the last trading period.
  • 德意志銀行於Check Point軟件技術有限公司(納斯達克：CHKP)，持有評級。Check Point Software的目標價設為128.00美元。Check Point軟件公司第二季度的利潤為1.58美元，而去年同期為1.38美元。Check Point Software目前的股票表現顯示，52周高點為130.65美元，52周低點為80.06美元。此外，在上一交易期結束時，收盤價為128.08美元。
  • 目前評級為跑贏大盤，Evercore ISI Group在8x8英寸(紐約證券交易所：EGHT)。目標價格似乎被設定為8x8的23.00美元。8x8第一季度的利潤為0.07美元，而去年同期為0.14美元。該股目前的52周高點為25.25美元，52周低點為10.70美元。上交易期尾盤，8/8收報16.28美元。
  • 摩根士丹利發起了關於阿卡迪亞製藥公司(納斯達克：ACAD)，評級超重。阿卡迪亞製藥的目標價定為55.00美元。第二季度，阿卡迪亞製藥公司的每股收益為0.27美元，而去年同期為0.38美元。Acadia PharmPharmticals目前的股票表現顯示，52周高點為58.72美元，52周低點為23.77美元。此外，在上一交易期結束時，收盤價為38.91美元。
  • 德意志銀行於Fortinet Inc.(納斯達克：FTNT)，持有評級。Fortinet的目標價定為131.00美元。Fortinet第二季度的利潤為0.82美元，而去年同期為0.58美元。Fortinet目前的股票表現顯示，52周高點為151.95美元，52周低點為70.2美元。此外，在上一交易期結束時，收盤價為129.51美元。
  • 李約瑟發起了關於VIR生物技術公司(納斯達克：VIR)，評級為買入。Vir Biotech的目標價定為62.00美元。VIR Biotech第二季度盈利0.27美元。目前，該股的股價為75.00美元的52周高點和11.65美元的52周低點。VIR Biotech上一交易期尾盤報50.43美元。
  • 摩根士丹利發起了關於Evofem生物科學公司(納斯達克：EVFM)，具有同等重量的評級。第二季度，Evofem Biosciences的每股收益為0.39美元，而去年同期為0.95美元。該股52周高點為7.50美元，52周低點為2.73美元。上一交易期尾盤，Evofem Biosciences收報3.36美元。
  • 在當前評級為串聯的情況下，Evercore ISI Group在Five9 Inc.(納斯達克：FIVN)。Five9的目標價格似乎被設定在122.00美元。第二季度，Five9的每股收益為0.21美元，而去年同期為0.20美元。該股的52周高點為131.98美元，52周低點為50.73美元。上一交易期尾盤，Five9收報124.59美元。
  • 奧本海默發起了關於富金特基因公司(納斯達克：FLGT)，表現優於大盤。Fulgent Genetics的目標價定為75.00美元。富金特基因公司第二季度的利潤為0.17美元，而去年同期為0.06美元。目前，該股的股價為47.85美元的52周高點和6.70美元的52周低點。富力遺傳上一交易期尾盤報44.01美元。
  • 高盛發起了關於屈曲治療公司(納斯達克：FLXN)，評級為中性。Flexion治療公司的目標價格定為15.00美元。Flexion治療公司第二季度的利潤為0.76美元，而去年同期為0.96美元。目前Flexion Treeutics的股票表現顯示，52周高點為22.98美元，52周低點為5.01美元。此外，在上一交易期結束時，收盤價為12.65美元。
  • 在目前評級為增持的情況下，富國銀行在Tandem糖尿病護理公司(納斯達克：TNDM)。Tandem糖尿病護理的目標價格似乎被設定在120.00美元。第二季度，Tandem糖尿病護理公司的每股收益為0.45美元，而去年同期為0.03美元。該股52周高點為110.80美元，52周低點為43.69美元。上一交易日尾盤，Tandem糖尿病護理公司收於107.33美元。
  • 貝倫伯格發起了關於伊頓公司PLC(紐約證券交易所：ETN)，持有評級。伊頓公司的目標價定為110.00美元。伊頓公司第二季度盈利0.70美元，而去年同期為1.53美元。目前，該股的52周高點為105.78美元，52周低點為56.41美元。伊頓公司上一交易期結束時收於100.48美元。
  • 在目前評級為買入的情況下，貝倫伯格在艾默生電氣公司(紐約證券交易所：電子病歷)。艾默生電氣的目標價似乎被設定在83.00美元。艾默生電氣第三季度每股收益為0.80美元，而去年同期為0.94美元。艾默生電氣目前的股票表現顯示，52周高點為78.38美元，52周低點為37.75美元。此外，在上一交易期結束時，收盤價為68.32美元。
  • 在目前評級為買入的情況下，貝倫伯格在羅克韋爾自動化公司(紐約證券交易所：韓方)。羅克韋爾自動化的目標價似乎被設定在270.00美元。第三季度，羅克韋爾自動化公司的每股收益為1.27美元，而去年同期為2.40美元。目前，該股的52周高點為238.49美元，52周低點為115.38美元。羅克韋爾自動化上一交易期尾盤報228.68美元。

譯文內容由第三人軟體翻譯。


以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
    搶先評論